Subscribe
istock-629794242xesai-1
Xesai / iStockphoto.com
19 October 2018Americas

Amgen injects £50m in UK gene-sequencing company

Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Europe
Oxford Nanopore signs CRISPR licence
20 September 2019   UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Europe
Oxford Nanopore signs CRISPR licence
20 September 2019   UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Europe
Oxford Nanopore signs CRISPR licence
20 September 2019   UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York